Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP229790.RAlFOoanqhgFrlaJmBNsrvjD_9Py78DSjYJLPHXDNSIiU130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP229790.RAlFOoanqhgFrlaJmBNsrvjD_9Py78DSjYJLPHXDNSIiU130_provenance.
• NP696429.RAulbjmboofo81m4CZPiP28rC8kANn_L89TWt4ihkXXKU130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP696429.RAulbjmboofo81m4CZPiP28rC8kANn_L89TWt4ihkXXKU130_provenance.
• NP917966.RAYQfzwFelq-M1oP1jY0I4uOAARRzjcqJqUNl3MT60bSk130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP917966.RAYQfzwFelq-M1oP1jY0I4uOAARRzjcqJqUNl3MT60bSk130_provenance.
• NP634453.RAqWXDjx7Re4WgkcZA4Gp5oe8Ntf43ZvBADnXsolhWn2A130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP634453.RAqWXDjx7Re4WgkcZA4Gp5oe8Ntf43ZvBADnXsolhWn2A130_provenance.
• NP291754.RAIEFBdzW99MeaG4CtcZA9RVTuj0CpDCRORcOJMbl_VvA130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP291754.RAIEFBdzW99MeaG4CtcZA9RVTuj0CpDCRORcOJMbl_VvA130_provenance.
• NP434958.RAaFCZZ6uvTQZ798CipI1LrGYZNq8POEpgk_4ah8sqKOM130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP434958.RAaFCZZ6uvTQZ798CipI1LrGYZNq8POEpgk_4ah8sqKOM130_provenance.
• NP302178.RA8GSgUGTvSafhiqg6Z12hXNrwQfD-uQn3Uha61myd82s130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP302178.RA8GSgUGTvSafhiqg6Z12hXNrwQfD-uQn3Uha61myd82s130_provenance.
• NP385811.RA-7-9zQ4nJCSeYISJjrL7CJ6xq6CsOvmoBWEwHnGSJhs130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP385811.RA-7-9zQ4nJCSeYISJjrL7CJ6xq6CsOvmoBWEwHnGSJhs130_provenance.
• NP385473.RALUwcR1l09OKkBnab95dHStisWGdZHQxCeEhKIwbA_es130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP385473.RALUwcR1l09OKkBnab95dHStisWGdZHQxCeEhKIwbA_es130_provenance.
• NP368510.RAcIq4iJGt7P6BaOl3zCQzkbRWmRSpamr3HI_5OtYFIBE130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368510.RAcIq4iJGt7P6BaOl3zCQzkbRWmRSpamr3HI_5OtYFIBE130_provenance.
• NP304401.RAZytmuBAopIByZrb-VwyPbqyCWDIOERuIyxRA11YsFxc130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP304401.RAZytmuBAopIByZrb-VwyPbqyCWDIOERuIyxRA11YsFxc130_provenance.
• NP614435.RAIpxXFtzJ4Xp6vNpwjlBmstvJBRcAVyU07H4YG9ye8Pg130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP614435.RAIpxXFtzJ4Xp6vNpwjlBmstvJBRcAVyU07H4YG9ye8Pg130_provenance.
• NP705712.RAaLKH9pGpOzWqihaxUrX_gwkxQvFjGa4b03tX8ZoxVpI130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP705712.RAaLKH9pGpOzWqihaxUrX_gwkxQvFjGa4b03tX8ZoxVpI130_provenance.
• NP705714.RAVxuSe1ll4zWjQ1qYK0O_obUZlebXMAFuzWRGW9N_uCM130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP705714.RAVxuSe1ll4zWjQ1qYK0O_obUZlebXMAFuzWRGW9N_uCM130_provenance.
• NP923278.RAOB5A-qI3Z-JiFusidvh1Iw_dNtMXTDTaZPewgyMkg2g130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP923278.RAOB5A-qI3Z-JiFusidvh1Iw_dNtMXTDTaZPewgyMkg2g130_provenance.
• NP705713.RAj9W5h4kRhA4NOyX__wAuyq8piwxWwvvVZ6p5YyCaYAM130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP705713.RAj9W5h4kRhA4NOyX__wAuyq8piwxWwvvVZ6p5YyCaYAM130_provenance.
• NP231932.RAFLRHE9S4tzDhIvp4jIc7zKvCgOfAXiXR0PE97xe8ugw130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP231932.RAFLRHE9S4tzDhIvp4jIc7zKvCgOfAXiXR0PE97xe8ugw130_provenance.
• NP705711.RAIrqLgMy57gztx8SGz-MvigciN7rR4Avsbhnpar8_nww130_assertion description "[Our results suggest that Brenner tumors and TCCs follow different tumorigenic pathways, whereas borderline and malignant Brenner tumors are low-grade neoplasms with activation of the PI3K/AKT pathway through EGFR, TCCs are high-grade tumors that have p53 mutations and p16 and p53 protein overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP705711.RAIrqLgMy57gztx8SGz-MvigciN7rR4Avsbhnpar8_nww130_provenance.